Related by context. All words. (Click for frequent words.) 68 ProLindac TM 67 ganetespib 67 farletuzumab 67 CBLC# 67 INCB# [001] 66 IMA# 66 picoplatin 66 MEK inhibitors 66 CR# vcMMAE 66 alvespimycin 66 CYT# 66 OncoVEX GM CSF 66 GAP #B# 66 Panzem R NCD 66 Azedra 65 Phase Ib II 65 Sym# 65 Azixa 65 deforolimus 65 pertuzumab 65 PXD# 65 Phase Ib 65 metaglidasen 65 Angiolix 65 HGS ETR1 65 NXL# 65 TPI ASM8 65 AEG# 65 Allovectin 7 64 Pertuzumab 64 EndoTAG TM -1 64 YONDELIS 64 preclinically 64 OMP #M# 64 phase IIa clinical 64 Onconase 64 OncoVEX 64 HuLuc# 64 Tarvacin TM 64 AP# [003] 64 tanespimycin 64 YONDELIS R 64 MOZOBIL 64 REOLYSIN ® 64 OvaRex ® MAb 64 Cobalamin 64 Nanobody 64 Archexin 64 CA4P 64 obatoclax 64 DXL# 64 Fodosine 64 Amplimexon 64 Alocrest 64 Civacir 64 Carfilzomib 64 ENMD # 64 DACH platinum 63 cancer immunotherapies 63 ATL# [001] 63 radiation sensitizer 63 OvaRex R 63 SERMs 63 entinostat 63 OXi# 63 torezolid phosphate 63 CEQ# 63 SNT MC# 63 Vivecon 63 Phase 1b trial 63 phase IIb clinical 63 neratinib 63 Exherin TM 63 elesclomol 63 AeroLEF TM 63 indibulin 63 Virulizin R 63 Phase Ib study 63 liposomal formulation 63 Perifosine 63 Reolysin 63 forodesine 63 HuMax EGFr 63 registrational trial 62 sapacitabine 62 Tyrima 62 vorinostat 62 Ceflatonin 62 novel VDA molecule 62 Proxinium TM 62 TG# [003] 62 Amrubicin 62 HuMax CD4 62 Lupuzor 62 polymerase inhibitors 62 HGS# 62 enzastaurin 62 RLY# 62 monoclonal antibody MAb 62 BCX# 62 MGCD# [001] 62 ixabepilone 62 Aphthasol R 62 therapeutic monoclonal antibody 62 axitinib 62 Cloretazine R VNP#M 62 Panzem NCD 62 Cloretazine 62 BAY #-# 62 Phase IIIb clinical 62 lapatinib Tykerb 62 Alpharadin 62 Panzem 62 Xanafide 62 Phase Ib clinical 62 Factor VIIa 62 vidofludimus 62 HQK 62 PEG SN# 62 protein kinase inhibitor 62 ponatinib 62 FOLOTYN ® 62 Icatibant 62 MAbs 62 PSMA ADC 62 Annamycin 62 NP2 Enkephalin 62 EndoTAGTM 1 61 JAK inhibitor 61 molecularly targeted 61 Dapagliflozin 61 RGB # 61 depsipeptide 61 Tarvacin 61 eprotirome 61 phase 2a 61 Phase IIa clinical 61 INT# [002] 61 talactoferrin 61 angiogenesis inhibitor 61 IMP# 61 CTAP# Capsules 61 IRX 2 61 perifosine 61 Loramyc R 61 ALN RSV# 61 Curaxin 61 Phase 2a trial 61 Allovectin 7 ® 61 Pazopanib 61 HCV protease inhibitors 61 Nexavar ® 61 nucleoside analog 61 hematological cancers 61 oral prodrug 61 ASONEP 61 Imprime PGG 61 triphendiol 61 vascular disrupting agent 61 Bafetinib 61 Marqibo TM 61 TREANDA 61 XmAb# 61 radezolid 61 novel DACH platinum 61 Phase #b/#a 61 S/GSK# 61 elvucitabine 61 carfilzomib 61 OMAPRO 61 photoprotective drug 61 BRAF inhibitor 61 ProSavin 61 IMGN# 61 eniluracil 61 TRO# 61 Taxotere ® 61 Mipomersen 61 personalized immunotherapy 61 oral antiviral 61 OHR/AVR# 61 seliciclib CYC# 61 Phase III clinical trials 61 PDE4 inhibitor 61 Litx 61 PRT# 61 Nanobody ® 61 ONCONASE 61 BNC# 61 Eribulin 61 orally bioavailable 61 elacytarabine 61 Telatinib 61 Phase IIa trials 61 Thiarabine 61 trastuzumab Herceptin 61 sorafenib tablets 61 Microplasmin 61 PEP# [003] 61 sunitinib malate 61 HuMax CD# 61 VNP#M 61 romidepsin 61 ZK EPO 61 sorafenib Nexavar 61 Symadex 61 novel anticancer 61 mertansine 61 elotuzumab 61 Pemetrexed 61 GRNVAC1 61 JAK inhibitors 61 ASA# 61 Aplidin 61 anti leukemic 61 Personalized Immunotherapy 61 Asentar 61 L BLP# 61 anticancer therapies 61 bevacizumab Avastin 61 Clolar ® 60 ELACYT 60 omacetaxine 60 danoprevir 60 Traficet EN 60 BrachySil TM 60 investigational therapies 60 registrational 60 Nexavar sorafenib 60 bortezomib Velcade 60 pralatrexate 60 vosaroxin 60 Virulizin ® 60 Allovectin 7 R 60 RDEA# 60 rNAPc2 60 amrubicin 60 Dacogen injection 60 NVA# 60 Revlimid lenalidomide 60 Solazed 60 Cloretazine ® 60 EndoTAG TM 60 ZYBRESTAT 60 favorable pharmacokinetic profile 60 IMC A# 60 bevacizumab Avastin ® 60 thymalfasin 60 Cotara 60 GRN#L 60 Panzem R 60 Satraplatin 60 Omacetaxine 60 OncoGel 60 DermaVir Patch 60 belinostat 60 ApoB SNALP 60 taxane 60 IL# PE#QQR 60 acyclovir Lauriad R 60 Amigal 60 Interferon alpha 60 dacetuzumab 60 huC# DM4 60 telbivudine 60 CobaCyte 60 Aplidin R 60 Phase 1b clinical 60 adipiplon 60 Myocet 60 CCX# 60 paclitaxel Taxol ® 60 JAK2 inhibitors 60 Pimavanserin 60 BioVant 60 cytotoxics 60 glufosfamide 60 ThermoDox R 60 RH1 60 olaparib 60 tesmilifene 60 atacicept 60 selective orally bioavailable 60 prostone 60 paclitaxel poliglumex 60 clofarabine 60 teriflunomide 60 TLR agonists 60 HDAC inhibitor 60 afamelanotide 60 anti angiogenic therapy 60 NEUGENE 60 Firazyr 60 bendamustine HCl 60 BENLYSTA ® 60 anti CD# antibodies 60 pomalidomide 60 phase IIb 60 Oxaliplatin 60 trastuzumab DM1 60 Tesmilifene 60 lumiliximab 60 Treanda 60 integrase inhibitor 60 proteasome inhibitor bortezomib 60 JP-#/fipamezole 60 nanoviricides 60 Hsp# inhibition 60 riociguat 60 Hsp# Inhibitor 60 EOquin TM 60 epigenetic therapies 60 Revimmune 60 Evoltra 60 Pervasis 59 UPLYSO 59 Aviptadil 59 Flutiform TM 59 KNS # 59 Bezielle 59 MyVax R 59 MEK inhibitor RDEA# 59 Urocidin 59 Clevudine 59 luliconazole 59 Etoposide 59 seliciclib 59 PS# [001] 59 ganaxolone 59 TASQ 59 Pirfenidone 59 Vidofludimus 59 velafermin 59 BrachySil 59 imetelstat 59 Glufosfamide 59 TG# [001] 59 DAVANAT 59 investigational compounds 59 Vandetanib 59 EndoTAG 59 ridaforolimus 59 GMX# 59 lintuzumab 59 AMPK activators 59 T DM1 59 PI3K/Akt pathway inhibitor 59 Erlotinib 59 tranilast 59 CYT# potent vascular disrupting 59 PLK1 SNALP 59 rFIXFc 59 evaluating tivozanib 59 Phase III trials 59 chemotherapeutic regimen 59 IPLEX 59 Velcade bortezomib 59 HGS ETR2 59 Phase IIa trial 59 tramiprosate Alzhemed TM 59 CoFactor 59 Diamyd ® 59 voclosporin 59 vascular disrupting agents 59 PRTX 59 oral taxane 59 Tavocept 59 ISIS # 59 bardoxolone 59 HspE7 59 LY# [003] 59 ulimorelin 59 GRN# 59 pharmacodynamic properties 59 relapsed multiple myeloma 59 Daclizumab 59 PROSTVAC TM 59 novel peptide 59 ocular formulation 59 OPAXIO 59 registrational studies 59 thalidomide Thalomid 59 vemurafenib 59 PEGylated 59 phase Ib 59 mapatumumab 59 VEGF Trap 59 Phase 1a clinical 59 docetaxel Taxotere 59 JAK2 inhibitor 59 EOquin 59 LEUKINE 59 tolevamer 59 Phase IIb clinical trials 59 tipranavir 59 PROCHYMAL 59 iSONEP 59 standard chemotherapy regimen 59 #D#C# 59 multitargeted 59 Quinamed 59 relapsed ovarian cancer 59 aflibercept 59 Sebivo 59 Aurexis 59 SIR Spheres 59 voreloxin 59 PEG Interferon lambda 59 R#/MEM # 59 HCV protease inhibitor 59 Thiovir 59 clinical trials 59 TRAIL receptor antibodies 59 oral salmon calcitonin 59 Neuradiab 59 WILEX 59 IRESSA 59 Gleevec resistant 59 TMC# [002] 59 huN# DM1 59 isoform selective 59 Darinaparsin 59 APTIVUS 59 Phase 2a 59 MEK inhibitor 59 Tarceva TM 59 ToGA 59 therapeutic monoclonal antibodies 59 Phase IIb trials 59 Solasia 59 NGX# 59 pharmacokinetic studies 59 Clavis Pharma 59 SUCCEED trial 59 TYZEKA 59 Cethrin R 59 A3 adenosine receptor 59 Trastuzumab 59 paclitaxel Taxol 59 Orazol 59 Exelixis compounds 59 BiTE antibody 59 antitumor activity 59 Paclitaxel 59 pegylated liposomal doxorubicin 59 INCB# [002] 59 otelixizumab 59 pegfilgrastim 59 GFT# 59 Marqibo 59 Ceflatonin R 59 panitumumab 59 HuMax TAC 59 Trofex TM 59 preclinical studies 59 THR beta agonist 59 Reverset 58 Vicinium TM 58 chemotherapeutic drug 58 Dasatinib 58 Neulasta ® 58 Azedra TM 58 docetaxel Taxotere R 58 TBC# 58 fluoropyrimidine 58 Phase 2b clinical 58 proteasome inhibitor 58 Chemophase 58 MitoQ 58 IMiDs R 58 oral ridaforolimus 58 Phase IIb 58 Abiraterone 58 Multiferon R 58 Evoltra ® 58 R#/MEM 58 Golimumab 58 Squalamine 58 CRLX# 58 Debio 58 bendamustine 58 Phase III clinical 58 cetuximab Erbitux ® 58 atrasentan 58 NEUGENE antisense 58 SUTENT 58 monoclonal antibody therapies 58 oxidative stress inducer 58 CDP# 58 DP b# 58 AAV vectors 58 ANA# 58 epothilones 58 BZL# 58 RhuDex ® 58 Safinamide 58 Voreloxin 58 TOCOSOL Camptothecin 58 ELND-#/AZD-# 58 AZILECT R 58 Phase 2b 58 StemEx R 58 Taxotere docetaxel 58 lorvotuzumab mertansine 58 Ixempra 58 Seliciclib 58 Relovair 58 phase IIa 58 ADVEXIN 58 preclinical efficacy 58 receptor tyrosine kinase inhibitor 58 Tykerb lapatinib 58 DCVax R 58 LymphoStat B 58 Exelixis XL# 58 Phase #/#a 58 ruxolitinib 58 LHRH antagonists 58 Alvesco R 58 GLPG# 58 talabostat 58 anticancer agents 58 Nanobodies 58 ISF# 58 Bendamustine 58 HCD# [002] 58 BGC# 58 THALOMID 58 tubulin inhibitor 58 selective kinase inhibitor 58 Elagolix 58 rindopepimut 58 histone deacetylase HDAC inhibitor 58 gemcitabine chemotherapy 58 Phase #/#a trial 58 Scancell 58 nucleoside reverse transcriptase inhibitor 58 immunotherapeutic vaccine 58 MAGE A3 ASCI 58 Erbitux cetuximab 58 histone deacetylase inhibitor 58 multicenter Phase II 58 Sphingomab 58 Apaziquone 58 ospemifene 58 TRISENOX 58 trastuzumab DM1 T DM1 58 crizotinib PF # 58 PLX# 58 satraplatin 58 oral deforolimus 58 antiangiogenic agents 58 PARP inhibitor 58 Loramyc ® 58 delafloxacin 58 Campath ® 58 sumatriptan DosePro 58 Lorianne Masuoka MD 58 targeting CD# 58 confirmatory Phase III 58 Delcath PHP System 58 TOCOSOL Paclitaxel 58 JAK1 58 oblimersen 58 Phase #b/#a clinical 58 cetuximab Erbitux 58 Phase IIb clinical 58 tezampanel 58 DCVax ® 58 Zerenex 58 ENMD 58 EFAPROXYN 58 milatuzumab 58 Phase 2a clinical 58 TH# [003] 58 GAMMAGARD 58 Vaxfectin 58 noninfectious uveitis 58 generation purine nucleoside 58 antisense drug 58 Blinatumomab 58 DOS# 58 RPL# 58 pediatric acute lymphoblastic 58 Raltegravir 58 Æterna Zentaris 58 Avastin bevacizumab 58 immunotherapeutic 58 cediranib 58 rhIL 7 58 subcutaneous formulation 58 AVE# 58 Ramoplanin 58 CIMZIA ™ 58 HSP# inhibitor 58 Intravenous CP 58 ZEVALIN ® 58 Arimoclomol 58 Deforolimus 58 oral bioavailability 58 tremelimumab 58 trodusquemine 58 Zingo TM 58 adecatumumab 58 SNALP technology 58 teduglutide 58 nanopharmaceutical 58 valopicitabine 58 EZN 58 LEP ETU 58 Insegia 58 Gefitinib 58 IAP inhibitors 58 GLYX 58 PrevOnco ™ 58 Genz # 58 CCR5 antagonist 58 Genasense ® 58 TriRima 58 telaprevir VX 58 ALN VSP 58 topical gel containing 58 ularitide 58 FOLOTYN 58 siRNA therapeutics 58 uric acid lowering 58 BAL# [001] 58 LentiVector technology 58 Chrysalin 58 tivozanib 57 Hycamtin 57 Celator 57 PCK# 57 BRIM3 57 Phase 1b clinical trials 57 interferon beta therapy 57 therapeutic regimens 57 HyACT 57 blinatumomab 57 Tarmogen 57 OMNARIS HFA 57 ofatumumab 57 Novosom 57 Phase 2b trial 57 Romidepsin 57 Plicera 57 TTF Therapy 57 incyclinide 57 Zybrestat 57 MAP# 57 Gleevec imatinib mesylate 57 MLN# 57 Japanese Encephalitis vaccine 57 Phase 1b 57 anticancer agent 57 KRN# 57 faropenem 57 methylnaltrexone 57 Anticalin ® 57 zanolimumab 57 TELINTRA 57 Hyphanox 57 HCV protease 57 Anthim 57 oral gallium 57 CRD5 57 Phase 2b clinical trials 57 celgosivir 57 phase IIb trial 57 AKT inhibitor 57 isavuconazole 57 Irinotecan 57 pan HDAC inhibitor 57 Azilect ® 57 Bortezomib 57 AzaSite Plus 57 preclinical 57 tiapamil 57 Tanespimycin 57 efficacy tolerability 57 immunomodulatory 57 tesetaxel 57 Vaxfectin TM 57 Campath alemtuzumab 57 bardoxolone methyl 57 clinical trial 57 targeted radiotherapeutic 57 Apoptone 57 Muraglitazar 57 Atiprimod 57 Junovan TM 57 boosted protease inhibitor 57 CYC# 57 2 methoxyestradiol 57 Rexin G 57 hematological indications 57 docetaxel chemotherapy 57 RG# [001] 57 Maribavir 57 AZILECT ® 57 ongoing Phase 1b 57 Hemospan 57 Memryte 57 anticancer compounds 57 cannabinor 57 Epanova 57 omacetaxine mepesuccinate 57 PREOS 57 dasatinib Sprycel 57 ADAGIO study 57 TLR8 agonist 57 anticoagulant reversing agent 57 CCR9 antagonist 57 Ridaforolimus 57 tezampanel NGX# 57 refractory metastatic 57 GW# [003] 57 regorafenib 57 investigational humanized monoclonal antibody 57 RE SURGE 57 convenient dosing regimens 57 BEXXAR 57 PHX# 57 pharmacokinetic PK study 57 Relivar 57 Ophena 57 PGL# 57 NNR Therapeutics 57 LibiGel ® 57 Phase 2b study 57 DR Cysteamine 57 antiviral activity 57 Heplisav 57 chemotherapeutics 57 carboplatin paclitaxel 57 GLP toxicology studies 57 cilengitide 57 BRIM2 57 fosbretabulin 57 durable remissions 57 Nimotuzumab 57 tyrosine kinase inhibitor 57 brentuximab vedotin 57 Tezampanel 57 tolerability profile 57 nitazoxanide 57 ORENCIA R 57 MYDICAR ® 57 galiximab 57 inecalcitol 57 histamine dihydrochloride 57 reslizumab 57 mTOR inhibitor 57 Leukine 57 taxane chemotherapy 57 Dalbavancin 57 antiviral compounds 57 platinum refractory 57 CCR5 mAb 57 dalbavancin 57 nilotinib Tasigna 57 ISENTRESS 57 iniparib 57 MDV# 57 Preclinical studies 57 LEVADEX ™ 57 orBec 57 Davanat 57 Cardio Vascu Grow 57 gemcitabine Gemzar 57 Benlysta belimumab 57 rALLy clinical trial 57 rxRNA 57 Nanobody R 57 Tracleer r 57 Everolimus 57 ZADAXIN 57 CytoFabTM 57 lomitapide 57 Increlex ® 57 peptidomimetic 57 p# inhibitor 57 docetaxel 57 intranasal delivery 57 vinca alkaloid 57 HDAC Inhibitor 57 ACZ# 57 antiangiogenesis 57 radiotherapeutic 57 Poly ICR 57 ZADAXIN ® 57 immatics 57 MGd 57 volociximab 57 ATL/TV# 57 Phase III Clinical Trials 57 ELND# 57 novel immunomodulatory 57 Tesetaxel 57 anticancer compound 57 antitumor efficacy 57 apaziquone 57 Excellarate 57 Serdaxin 57 OX1 57 mitogen activated ERK kinase 57 investigational compound 57 daclizumab 57 resminostat 57 ONCONASE R 57 StemEx 57 Tarceva erlotinib 57 Aurora kinase inhibitor 57 Radilex 57 CDK inhibitors 57 Alzhemed TM 57 daptomycin 57 TAFA# 57 bortezomib Velcade R 57 rilonacept 57 Onalta 57 NEUMUNE 57 HER2 positive metastatic breast 57 LIVALO 57 topical ophthalmic 57 ozarelix 57 SinuNase TM 57 PEGylated interferon beta 1a 57 proteasome inhibitors 57 Taxol ® 57 synthetic peptides 57 ThermoDox 57 retaspimycin 57 Maraviroc 57 C1 INH 57 telomerase therapeutic 57 afatinib 57 GALNS 57 Elocalcitol 57 Onco TCS 57 Novartis Gleevec 57 TELCYTA 57 DCVax Brain 57 AEGR 57 RNAi therapeutic targeting 57 demonstrated antitumor activity 57 mAbs 57 MT#/MEDI-# 57 GRASPA ® 57 SCIB1 57 favorable tolerability 57 Fleximer 57 DCVax R Brain 57 Nanobodies R 57 Vidaza ® 57 Phase IIb trial 57 Boceprevir 57 evaluating satraplatin 57 Restanza 57 PD LID 57 histone deacetylase HDAC 57 multicenter randomized placebo controlled 57 humanized antibody 57 Allovectin 7 r 56 REYATAZ R 56 Emselex 56 sorafenib Nexavar ® 56 NNRTIs 56 PEGPH# 56 Inhalation Solution 56 cMET 56 Hsp# inhibitor 56 synthetic siRNA 56 NanoCrystal technology 56 viral kinetics 56 nimotuzumab 56 CVac 56 apricitabine 56 Nicole Onetto MD 56 M6G 56 Zolinza 56 Cysteamine 56 Spiegelmer ® 56 Plenaxis TM 56 randomized controlled Phase 56 Shigamabs ® 56 Excellagen 56 Temsirolimus 56 apoptosis inducer 56 recurrent ovarian cancer 56 antisense inhibitors 56 Sanofi Aventis Taxotere 56 ThermoDox ® 56 custirsen 56 PNP inhibitor 56 allosteric modulator 56 Xeloda capecitabine 56 fluoroquinolone antibiotic 56 ceftaroline 56 FluCide 56 VA# [002] 56 Aflibercept 56 anti angiogenic agents 56 gemcitabine carboplatin 56 Ocrelizumab 56 selective inhibition 56 DCVax ® Brain 56 ThGRF 56 Zadaxin 56 SAR# [004] 56 SLx 56 chemotherapy cisplatin 56 RP# [002] 56 zalutumumab 56 Hepatocellular Carcinoma HCC 56 VDAs 56 DermaVir 56 Ferumoxytol 56 capecitabine Xeloda R 56 Leukine ® 56 BCR ABL inhibitors 56 CD# CEA 56 PSN# [002] 56 ONCASPAR 56 ocrelizumab 56 erlotinib Tarceva ® 56 preclinical toxicology 56 MVA BN R 56 immune modulating 56 predictive biomarkers 56 OnDose TM 56 Cimzia ® certolizumab pegol 56 ALN PCS 56 Alemtuzumab 56 Trofex 56 GnRH antagonist 56 Varespladib 56 oncology indications 56 Catena ® 56 REP# 56 ABRAXANE TM 56 CINQUIL 56 HIF PH inhibitors 56 evaluating REVLIMID 56 MabCampath 56 SYN# 56 Immunotherapeutic 56 drug GAP #B# 56 Doxorubicin 56 JAK3 56 REVLIMID 56 drug ISA# 56 liprotamase 56 LymphoStat B TM 56 eTag assays 56 Ixabepilone 56 orally dosed 56 fidaxomicin Phase 3 56 liposomal doxorubicin 56 Mycamine 56 Phase IIa 56 Herceptin trastuzumab 56 AZX# 56 CORT # 56 myeloproliferative disorders 56 Fludara ® 56 Cylene 56 IgG1 antibody 56 temozolomide 56 Campath 56 gefitinib Iressa 56 AEZS 56 SRT# [003] 56 PF # [001] 56 renin inhibitors 56 overlapping toxicities 56 Fx #A 56 Cethrin 56 amifampridine phosphate 56 Aclidinium 56 BARACLUDE R 56 oral FTY# 56 molecular entities NMEs 56 AQ4N 56 AVN# [001] 56 protease inhibitor PI 56 bortezomib Velcade ® 56 tolerability 56 NO# [002] 56 Zebinix R 56 prophylactic vaccines 56 ZD# [001] 56 ceftazidime 56 Celgene Revlimid 56 investigational monoclonal antibody 56 ACV1 56 budesonide foam 56 vicriviroc 56 Tracleer R